Objective Emerging evidence suggests that comorbidity may influence disability outcomes in multiple sclerosis (MS); we investigated the association between psychiatric comorbidity and MS disability progression in a large multiclinic population.
Psychiatric comorbidity is common in multiple sclerosis (MS), but is often overlooked and undertreated. 1 Bipolar disorder, anxiety, and depression all occur at much higher rates than expected in the general population.
1,2 The WHO's "World Health Survey" suggests that depression coexisting with a chronic disease leads to significantly greater disease burden and disability compared to having either depression or a chronic disease alone. 3 The negative effect of psychiatric comorbidity on quality of life in persons with MS is well-recognized, 4 but little is known about the extent of its effect on disability progression. 5 The rate of disability progression is challenging to predict and few modifiable factors have been identified. 6 Establishing factors that account for some of the variability in progression would be useful to patients and clinicians alike, for estimating prognoses and planning management strategies. We aimed to investigate the effect of psychiatric comorbidity on neurologic disability progression, as measured by the Expanded Disability Status Scale (EDSS), in a large multiclinic cohort using linked clinical and health administrative databases.
Methods

Design and setting
This long-term retrospective cohort study employed several linked MS-specific clinical and population-based health administrative databases. Cases were selected from the British Columbia Multiple Sclerosis (BCMS) database and the Dalhousie Multiple Sclerosis Research Unit (DMSRU) database in Nova Scotia (NS). Combined, these provinces represent approximately 15% of the Canadian population. The BCMS database contains information from all 4 MS clinics in the province (up until January 2005, when a fifth unlinked clinic opened). The DMSRU is the only site of specialty MS care in the province of NS, with an estimated case ascertainment of 83%. 7 Both databases contain clinical and demographic information, including disability (EDSS scores, measured by MS-specialist neurologists, trained and certified as EDSS assessors), date of MS symptom onset, disease course (relapsing or progressive-onset), date of birth, and sex. First, province-wide registry files (British Columbia [BC] Registration and Premium Billing Files 8 and NS Insured Patient Registry) were used to determine a person's residency within each province. Neighborhood-level socioeconomic information (Census Geodata 9 in both provinces), physician claims (BC Medical Service Plan 10 and NS Medical Service Insurance databases), hospital claims (Discharge Abstract Database 11 in both provinces), and disease-modifying therapy (DMT) prescription records (PharmaNet 12 and DMSRU database) were linked at the individual level. Physician and hospital databases included diagnoses coded according to the ICD-9/10-CA. All data from BC were linked and identifiers were removed before analysis by Population Data BC, a provincial-wide population data platform (popdata.bc.ca). In NS, DMSRU clinical data and NS administrative health data were linked via personal health identification numbers by the NS Department of Health and Wellness; encrypted linked files were transferred to Health Data Nova Scotia (medicine.dal. ca/departments/department-sites/community-health/research/hdns.html), where all analyses were conducted.
Study population
The study cohort included individuals aged 18 years or older at MS symptom onset who were diagnosed with MS by a neurologist according to the prevailing criteria at diagnosis. Complete data were available from April 1991 to December 2008 in BC and January 1990 to December 2013 in NS. The cohort entry date was 2 years prior to the date of MS symptom onset. Therefore, MS symptom onset occurred between April 1993 in BC or January 1992 in NS and December 2004 in BC or December 2010 in NS (to allow sufficient follow-up time). Individuals were followed to the earlier of last recorded EDSS, emigration from the province (>90 consecutive days not registered in the provincial health plan), or the study end. Individuals with <2 EDSS measurements during the study period were excluded.
Defining psychiatric comorbidities
Psychiatric comorbidities were identified using a validated algorithm of hospital and physician diagnostic codes. 13 First, an omnibus definition of mood or anxiety disorders was employed, which included depression, anxiety, and bipolar disorder. This definition required ≥5 physician claims or ≥1 hospital claim for at least one of the listed disorders within a 5-year period. The first claim for a psychiatric comorbidity was considered the date of diagnosis. This date was used to determine whether the comorbidity was present or absent. Once the definition was reached, it was considered present for the remainder of followup due to the recurrent nature of these conditions. Second, the individual effects of depression, anxiety, and bipolar disorder were explored using the same approach as that for the omnibus definition (ICD codes for all case definitions and algorithms in table e-1, links.lww.com/WNL/A345).
Measuring disability progression
To maximize the power of the available data, we used all EDSS assessments and treated the EDSS as a continuous variable.
14 Glossary BC = British Columbia; BCMS = British Columbia Multiple Sclerosis; CI = confidence interval; DMSRU = Dalhousie Multiple Sclerosis Research Unit; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; GEE = generalized estimating equations; ICD = International Classification of Diseases; MS = multiple sclerosis; MSSS = Multiple Sclerosis Severity Score; NS = Nova Scotia; SES = socioeconomic status.
EDSS scores were recorded prospectively by the neurologist at a person's clinic visit. As a complementary approach to assessing disability, the Multiple Sclerosis Severity Score (MSSS) was calculated and assessed in one province (BC). 15 The MSSS is a continuous variable created using an algorithm that relates EDSS scores to the distribution of disability in patients with comparable disease durations from the local population (possible range 1-10). 15 
Statistical analysis
Due to privacy regulations that prevent line-level data from leaving the province of origin, analyses were performed in parallel at each site. The association between psychiatric comorbidity status and disability was examined using multivariable linear regression techniques, fitted using an identity link with generalized estimating equations (GEE). An exchangeable working correlation structure was used to account for dependence of observations within individuals. Findings were reported as β-coefficients with 95% confidence intervals (CI). All model assumptions were tested and met. The GEE model has fewer assumptions than mixed models, and generates risk estimates that are population averages of withinand between-subject effects, but are generally dominated by between-subject effects. In addition, the GEE model maximized sample size as we did not lose persons to left-censoring, allowed us to use all available EDSS scores, and effectively captured fluctuations in the EDSS over time. A complementary survival analysis was attempted, but ultimately not included as it did not meet the assumptions of Cox proportional hazards regression, and because of other described limitations of this approach in the context of measuring MS progression. 16 To better estimate within-person effects over time, thereby indicating the effect of acquiring psychiatric comorbidity on disability, we used a modified GEE model, which assessed change in EDSS relative to change in status of the covariates, as a complementary analysis. 17 Covariates were included in the model if they had established associations with progression (age at onset, sex, disease duration, disease course [relapsing-onset vs primary progressive], and DMT use [any vs none]), or reached a threshold level of statistical significance (p < 0.1) (socioeconomic status). Timevarying covariates were estimated at the time of each EDSS assessment, and included disease duration, DMT exposure (categorized as yes, no), and a count of physical comorbidities (categorized as 0, 1, 2, or ≥3). The physical comorbidities included diabetes, epilepsy, heart disease, hyperlipidemia, hypertension, and chronic lung disease, chosen based on their potential effects on disability progression 18 and availability of a validated algorithm for their identification in administrative health data (table e-1, links.lww.com/WNL/A345). [19] [20] [21] Results from the 2 provinces were combined using a randomeffects meta-analytic approach. Heterogeneity between provinces was measured using the I 2 statistic.
Analyses were performed using SAS Statistical Software Package 9.4 (SAS Institute Inc., Cary, NC), except for the meta-analyses and MSSS, which were done in R using the "metafor" and "ms.sev" packages. 
Results
Over the study period, 2,312 incident MS cases met inclusion criteria (1,248 in BC and 1,064 in NS) (figure e-1, links.lww. com/WNL/A344). The majority of individuals were women, with a relapsing-onset disease course, and an average age at MS symptom onset of 36.9 years (table 1) . Demographics were similar between the 2 provinces; however, as the average follow-up was longer in NS (and more contemporary), there was a higher proportion of participants who used a DMT relative to BC (72% vs 52%, p < 0.0001). As well, NS had a lower proportion with relapsing-onset MS relative to BC (90% vs 94%, p = 0.0001), and a different distribution of socioeconomic status (SES) (p < 0.0001) (table e-2, links. lww.com/WNL/A345).
The average follow-up time was 10.5 years (SD 4.3); within this period, the mean number of EDSS assessments was 6.7 (SD 4.6). During follow-up, 827 (35.8%) met criteria for a mood or anxiety disorder. While the majority of mood or anxiety disorders began following MS onset, 360/827 (43.5%) met criteria prior to their MS onset. Most met the definition based on physician encounters, while a small proportion (42/827; 5.1%) were hospitalized primarily for a mood or anxiety disorder. When the criteria for individual psychiatric disorders were examined, depression was the most common (37.0% ever affected), followed by anxiety (22.1%) and bipolar disorder (5.1%) (table 1) .
Using the omnibus definition, the presence of a mood or anxiety disorder was associated with a higher EDSS score (β-coefficient = 0.24, p = 0.002, adjusted for disease duration; and 0.28, p = 0.0002, adjusted for disease duration and course, age, sex, SES, physical comorbidity count, and DMT exposure; I 2 = 0.0% for both models). While the direction of effect was the same for both sexes, findings were significant only among women (β-coefficient = 0.31, p = 0.0004; I 2 = 0.0%),
but not men (β-coefficient 0.22, p = 0.17 I 2 = 0.0%) (table 2) . Results from each province are available in tables e-3 and e-4 (links.lww.com/WNL/A345).
Using the separate case definitions of depression, anxiety, and bipolar disorder, only the former was significantly associated with a higher EDSS score in the unadjusted and adjusted analyses (adjusted β-coefficients: 0.24, p = 0.001; 0.11, p = 0.21; and 0.29, p = 0.08, respectively) (table 3), although the estimated β-coefficients were similar. All 3 analyses resulted in I 2 values of 0.0%, suggesting the variability between provinces was due to chance.
The 
Discussion
Psychiatric comorbidities were common in our incident MS cohort. Overall, more than one-third of the 2,312 MS cases were found to have a mood or anxiety disorder. Presence of these comorbid conditions was associated with significantly higher subsequent disability over an average of 10 years of follow-up. The association between psychiatric comorbidity and disability persisted even after accounting for sex, age at MS onset, disease duration, disease course, SES, DMT use, and physical comorbidities. The effect was statistically significant among women, but not men, the latter of whom represented 24% of the study sample. When exploring the individual effect of each psychiatric comorbidity, depression arose as the only significant moderator of disability. While both anxiety and bipolar disorder were associated with a higher EDSS score, neither association met statistical significance, possibly due to the smaller numbers of persons affected.
Despite the high proportion of individuals with MS who have comorbid psychiatric disorders, studies exploring the longerterm effects of these conditions are limited and the consequences of comorbid psychiatric disorders for neurologic disability progression are not well-understood. In other chronic diseases, such as HIV, depression has been associated with increased disease progression. 22 While similar relationships may exist in MS, 23 the current knowledge regarding mental health and MS disability has largely been derived from crosssectional studies based in Europe and North America. Of the 9 studies found, 6 reported a positive association between mental health and disability status, 24-29 while 3 found none. [30] [31] [32] Five of the positive findings were cross-sectional, and all relied on self-reported psychiatric conditions or psychometric scales rather than clinical diagnosis. [24] [25] [26] 28, 29 Two cross-sectional studies reported no relationship. 30, 32 Conflicting results were found among the 2 longitudinal studies, one of which used a patient-reported disability outcome, 27 while the other examined secondary progressive MS onset. 31 In the former longitudinal study, 269 persons with relapsing-remitting MS completed the Hospital and Anxiety Depression Scale and the Multiple Sclerosis Walking Scale-12 at 3 time points over 2 years; they reported a significant reciprocal relationship between depressive symptoms and walking impairment. 27 In the latter study, baseline depression scores (from the Center for Epidemiological Studies Depression Scale) did not predict risk of secondary progressive MS among 149 persons who were followed for 10 years. 31 Elevated ratings on depression Disease duration at first EDSS, y, mean (SD) 2.7 (2.6)
Follow-up time (2-years pre-MS onset to last available EDSS), y, mean (SD)
(4.3)
First EDSS score, median (interquartile range) 2.0 (1.5-3.0)
Ever exposed to disease-modifying therapy, n (%) symptom scales may be short-lived, situationally determined, and not necessarily indicative of a mental disorder. This may explain some of the negative findings. Also, these studies had a much smaller sample size than the current one, and may have lacked power to detect an effect.
Our novel study attempts to elucidate a temporal relationship between psychiatric disorders and MS. While our findings suggest that the presence of a psychiatric disorder contributed to a subsequent increase in EDSS, a bidirectional relationship remains possible. For some individuals, a psychiatric condition may either develop or be more readily diagnosed in response to worsening disability. Further, when we assessed the change in psychiatric comorbidity status and the subsequent change in EDSS, findings did not reach significance, suggesting that the results could have been driven by the population-level, between-person effects as opposed to the effect of an individual acquiring a psychiatric disorder.
The high prevalence of psychiatric disorders in MS and their association with disability may reflect both biological and psychosocial factors. Evidence for shared underlying pathophysiologic processes includes reports that persons with MS with major depression have more T2-weighted lesions, a proxy for disease burden, than persons without. 33 Outside of MS, a meta-analysis of 225 studies found that major depressive disorder was associated with smaller volumes of the thalamus, hippocampus, basal ganglia, frontal lobe, orbitofrontal cortex, and gyrus rectus, 34 and anxiety has been associated with decreased gray matter volume. 35 Inflammatory dysregulation has been implicated in depressive disorders 36 and bipolar disorder 37 and is a central component of MS disease pathology. The presence of depression could be a direct (biological) reaction to increased inflammation, 36 which in turn leads to increased neurodegeneration and disability progression. 38 Psychiatric comorbidities may contribute to maladaptive coping strategies, and poor health behaviors, which could alter the course of MS. For example, depressed and anxious individuals are more likely to smoke, 39 a potential risk factor for MS disability worsening. 40 Depression and anxiety are more common in women, and the relationship between mood or anxiety disorders and disability in our study only reached statistical significance among women. It is possible that because a mental health condition had to be medically recognized our findings are, in part, driven by sex differences either in mental health help-seeking behaviors or readiness of practitioners to diagnose mental health conditions in women. 41 Second, because on average, men with MS progress faster in their disease than do women, 6 this combined with the lower number of men may have reduced our ability to detect an effect.
Strengths of this study include a large, representative cohort of clinic-attending persons with MS. Virtually all data were prospectively collected, with the exposure and outcomes collated independently, thereby effectively eliminating the potential for recall and related biases. Selection bias was also minimized by the broad criteria for inclusion.
We used a highly specific case definition for mood or anxiety disorders, which may have missed some individuals, such that our estimates of the relationship between psychiatric conditions and disability may be conservative. Another limitation of this study is the use of the ordinal EDSS as a linear scale. A change on the EDSS can have clinically different meanings depending on where on the scale it occurs, and the probability of progression is not necessarily evenly distributed along the scale. However, the interpretation of findings remained the same when we employed MSSS, which has linear scaling properties. 15 We did not have information on mental health symptom severity or adequacy of treatment, which may also contribute to these relationships and should be pursued in future studies. As well, it would be valuable to examine the effect of psychiatric comorbidity on alternative clinical outcome measures, such as the more extensive Multiple Sclerosis Functional Composite score.
Psychiatric comorbidities were common in this MS cohort and were associated with greater disability over time. This was particularly true for women. MS disease progression is highly variable, and these results suggest that psychiatric comorbidities may explain some of the heterogeneity between individuals. The importance of recognizing psychiatric comorbidities in persons with MS and optimizing their treatment is clear, both from the perspective of improved quality of life and disability reduction.
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